| Date Filed | Type | Description |
| 08/11/2023 |
4
| MCGUIRE TERRANCE (Director) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Sold 8 shares
@ $3.395, valued at
$27.2 |
|
| 05/22/2023 |
4
| Hecht Peter M (CEO) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 225,000 shares
@ $8.68, valued at
$2M
Granted 351,037 convertible preferred
@ $0 |
|
| 07/27/2022 |
4/A
| Hyman Steven (Director) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 57,753 options to buy
@ $0.78, valued at
$45k
|
|
| 07/26/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/26/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/24/2022 |
4
| Busch Andreas (Chief Scientific Officer) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 135,000 options to buy
@ $1.21, valued at
$163.4k
|
|
| 01/24/2022 |
4
| Gjino Anjeza (CFO) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 135,000 options to buy
@ $1.21, valued at
$163.4k
|
|
| 01/24/2022 |
4
| Hecht Peter M (CEO) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 52,950 options to buy
@ $1.78, valued at
$94.3k
Granted 430,000 options to buy
@ $1.21, valued at
$520.3k
|
|
| 01/24/2022 |
4
| Gault Cheryl (COO) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 135,000 options to buy
@ $1.21, valued at
$163.4k
|
|
| 12/10/2021 |
4
| Busch Andreas (Chief Scientific Officer) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 75,000 options to buy
@ $1.93, valued at
$144.8k
|
|
| 12/10/2021 |
4
| Gjino Anjeza (CFO) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $1.93, valued at
$193k
|
|
| 12/10/2021 |
4
| Gault Cheryl (COO) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $1.93, valued at
$193k
|
|
| 06/28/2021 |
4
| Lovell Stephanie (Director) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $3.97, valued at
$39.7k
|
|
| 06/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2021 |
4
| Isacson Ole (Director) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $3.97, valued at
$39.7k
|
|
| 06/28/2021 |
4
| Churchwell Kevin (Director) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $3.97, valued at
$39.7k
|
|
| 06/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/19/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 05/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/06/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|